Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study unconfirmed

Story checked

Real-world data reveals higher reported GLP-1 side effects in female patients (opens in a new tab)

news-medical.net · 2026-10-01

Short answerEvidenceSource

Short answer

Source study unconfirmed

No confirmed study match.

We couldn’t confidently identify the source study behind this story. This leaves its claims unverified — not disproven.

15 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

No single source study could be confirmed.

We could not identify a single source study for this article. It may discuss broader research or report findings from a source other than a research paper.

Open claim evidence
3

Search result

Source study unconfirmed.

We could not identify a single source study for this article. It may discuss broader research or report findings from a source other than a research paper.

The literature search

15 candidate papers

Papers surfaced in our search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 11 more search results
Then inspect each claim

Evidence layer

Claim by claim

What the story asserts. With no source study, there is nothing to check these against.

Claim 1 of 5Not checkedA second paper in a series presented at the EASD meeting and published in The Lancet Obstetrics, Gynaecology & Women's Health addresses wide-ranging issues relating to GLP-1 receptor agonist use in women and issues a call to action to improve the evidence base worldwide.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 2 of 5Not checkedWeight loss with GLP-1 receptor agonists is greater in women than in men, while improvements in blood sugar control are comparable.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 3 of 5Not checkedReal-world studies comparing adverse event rates have shown a higher overall frequency of reported side effects in women, including headache, vomiting, and dizziness, even though placebo-controlled trials suggest similar rates in both sexes.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 4 of 5Not checkedThe authors say more studies are needed to quantify side-effect profiles in women and develop mitigation strategies, and they recommend routine screening for depression, anxiety, and eating disorders before treatment and during follow-up.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 5 of 5Not checkedThe paper argues that equitable access to GLP-1 receptor agonists remains limited in many low- and middle-income countries, where nearly 80% of eligible adults live but retail prices can exceed $90 per month.View evidenceHide evidence

As statednearly 80%; more than $90 per month

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Finally, the search trail

Method layer

No single source study was found.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

PubMed, Europe PMC, Crossref · 15 candidate papers

Explore all search results